<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00774332</url>
  </required_header>
  <id_info>
    <org_study_id>C-011</org_study_id>
    <nct_id>NCT00774332</nct_id>
  </id_info>
  <brief_title>A Phase II Study of CODOX-M/ IVAC in Relapsed/Refractory ALL</brief_title>
  <official_title>A Phase II Study of CODOX-M/ IVAC in Relapsed/Refractory ALL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cooperative Study Group A for Hematology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cooperative Study Group A for Hematology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase II Study of CODOX-M/ IVAC in Relapsed/Refractory ALL
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The feasibility will be evaluated in terms of complete remission rate, duration of complete
      remission, disease-free survival, overall survival, and toxicities.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2006</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of complete remission, disease-free survival, overall survival, toxicities</measure>
    <time_frame>2009</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">37</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CODOX-M</intervention_name>
    <description>Cytoxan,Mesna,Adriamycin,Vincristine,Methotrexate,Leucovorin,Cytarabine</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with relapsed/resistant acute lymphoblastic leukemia

          -  Patients must be between 15 and 65 years of age.

          -  Estimated life expectancy of more than 3 months

          -  ECOG performance status of 2 or lower, Karnofsky scale &gt; 60 (see appendix I)

          -  Adequate cardiac function (EF&gt;45%) on echocardiogram or MUGA scan

          -  Adequate kidney function (estimated Ccr &gt;50 ml/min)

        Exclusion Criteria:

          -  Patients with CNS involvement of leukemic blasts will not be excluded.

          -  Patients with extramedullary relapse(s) only will be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jung-Hee Lee, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jung-Hee Lee, doctor</last_name>
    <phone>82-2-3010-5794</phone>
    <email>jhleecr@amc.seoul.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jung-Hee Lee, Doctor</last_name>
      <phone>82-2-3010-5794</phone>
      <email>jhleecr@amc.seoul.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 15, 2008</study_first_submitted>
  <study_first_submitted_qc>October 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2008</study_first_posted>
  <last_update_submitted>October 15, 2008</last_update_submitted>
  <last_update_submitted_qc>October 15, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2008</last_update_posted>
  <responsible_party>
    <name_title>Yeungnam University College of Medicine</name_title>
    <organization>Yeungnam University College of Medicine</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

